Levis throws 2 TD passes to help Titans outlast Texans 32-27United Internet AG ( OTCMKTS:UDIRF – Get Free Report ) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 2,200 shares, a drop of 83.6% from the November 30th total of 13,400 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days. United Internet Stock Performance OTCMKTS:UDIRF opened at $15.89 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.99 and a current ratio of 1.06. The firm has a market cap of $2.98 billion, a price-to-earnings ratio of 99.32 and a beta of 0.67. United Internet has a 52 week low of $15.55 and a 52 week high of $15.89. The firm has a 50-day moving average price of $20.56 and a two-hundred day moving average price of $23.62. About United Internet ( Get Free Report ) Read More Receive News & Ratings for United Internet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Internet and related companies with MarketBeat.com's FREE daily email newsletter .Feyenoord pick up a convincing 4-2 win against Sparta Prague in the Champions League
While the rest of the Notre Dame community figures out whether it's worth paying four figures for a ticket to the College Football Playoff first-round home game against Indiana, the men's basketball team continues to figure out how to survive without Markus Burton. Notre Dame (5-5) hosts its next-to-last nonconference game Wednesday night against Dartmouth (4-4), which plays its sixth contest of a seven-game road trip. The Fighting Irish took a promising step -- and snapped a five-game losing streak -- on Saturday by edging Syracuse 69-64 in their ACC opener. "We needed to be in a close game and we needed to win a close game so our guys can build some belief back," head coach Micah Shrewsberry said. "We can't take any steps back on Wednesday." Without Burton -- the stat sheet-stuffing sophomore point guard who injured the medial collateral ligament in his knee Nov. 26 against Rutgers -- the Irish are struggling to find someone to run the offense, as evidenced by their seven assists versus 15 turnovers against Syracuse. At the same time, players are filling the scoring void. Braeden Shrewsberry poured in a career-high-tying 25 points versus the Orange while hitting 6 of 11 3-point attempts. Tae Davis averaged 12.4 points and 7.2 shots per game when Burton was healthy, but he has upped his mean production to 16.6 points and 12.2 shots in the past five games. Micah Shrewsberry, though, prefers to measure progress on a possession-by-possession basis. "Just the toughness," he said. "There have been times when we haven't gotten the key stop. We haven't gotten the bucket when we quite need it. It gets deflating sometimes." Dartmouth knows that feeling. On Sunday, the Big Green took a one-point lead with 4:03 left in overtime at UIC -- and then failed to score on their final six possessions to suffer a 69-68 loss. The Big Green, who haven't posted a winning season since 1998-99, believe whole-heartedly in launching 3-pointers as they take 48 percent of their shots from behind the arc. Senior Cade Haskins (13.6 ppg) has hit a team-high 28 of 68 3-pointers this season, though fellow senior Ryan Cornish stacks up as the team's top scorer (14.3 ppg), passer (3.0 assists per game) and defender (2.3 steals per game). In its only previous game against a power-conference opponent, Dartmouth upset Boston College 88-83 on Nov. 29. --Field Level Media‘Your Allegation Is Baseless’ – APC Fires PDP Over Allegation Of Destroying Party’s Secretariat
Week 12's Sunday Night Football matchup features two teams fighting for positioning in the NFC playoffs, as the Rams host the Eagles to cap Sunday's action. The Eagles enter the game aiming for the top seed in the NFC. Philadelphia is 8-2 and one game back of the Detroit Lions for the No. 1 spot in the conference. The Eagles are currently on a six-game winning streak, which includes two straight wins over division rivals Washington and Dallas. In his first season for the Eagles, Saquon Barkley has been a star, already rushing for 1,137 yards and eight touchdowns on 187 carries. On the receiving side, A.J. Brown missed three games earlier this year but has still totaled 33 catches for 618 yards and three touchdowns. STREAM: Watch Eagles vs. Rams live on Fubo (free trial) As for the Rams, they continue to fight for a playoff spot with a 5-5 record. L.A. is locked in a three-team tie for second place in the NFC West, one game behind the 6-4 Cardinals. Los Angeles began the season 1-4, but it's 4-1 in its past five games to get back into the playoff conversation. The Rams have gotten healthier over the past month, with Cooper Kupp and Puka Nacua leading the passing attack. Veteran quarterback Matthew Stafford has played in every game this year, producing 2,557 passing yards with 13 touchdowns and seven interceptions. The Sporting News tracks the live score, updates, and highlights in Sunday Night Football between Philadelphia and Los Angeles. NFL HQ: Live NFL scores | Updated NFL standings | Full NFL schedule Eagles vs. Rams box score 1 2 3 4 F Eagles Rams Eagles vs. Rams live updates 6:05 p.m.: Saquon Barkley has arrived in Los Angeles ready for the game. Suited Saquon Sunday 👔 @saquon | #FlyEaglesFly pic.twitter.com/3Jt531mbRz What time does Eagles vs. Rams start? Date: Sunday, Nov. 24 Time: 8:20 p.m. ET For the second straight week, Sunday Night Football will be live from SoFi Stadium, this time with the Rams hosting the Eagles at 8:20 p.m. ET, 5:20 p.m. local time. How to watch Eagles vs. Rams TV Channel: NBC (U.S.) | TSN 1/3/4/5, CTV (Canada) Streaming: Peacock, Fubo (U.S.) | DAZN (Canada) NBC will once again have the call for Sunday Night Football, giving viewers the option to stream on Peacock. For those who don't have access to NBC or Peacock, Fubo, which offers a free trial to new users , is another streaming option available. STREAM: Watch Eagles vs. Rams live on Fubo (free trial) Eagles 2024 schedule Here is a look at the rest of the Eagles schedule this season. Suited Saquon Sunday 👔 @saquon | #FlyEaglesFly pic.twitter.com/3Jt531mbRz Date Opponent Time Dec. 1 @ Baltimore Ravens 4:25 pm. ET Dec. 8 vs. Carolina Panthers 1:00 p.m. ET Dec. 15 vs. Pittsburgh Steelers 4:25 p.m. ET Dec. 22 @ Washington Commanders 1:00 p.m. ET Dec. 29 vs. Dallas Cowboys 4:25 p.m. ET TBD vs. New York Giants TBD Rams 2024 schedule Here is who the Rams will play to end the year. Date Opponent Time Dec. 1 @ New Orleans Rams 4:05 p.m. ET Dec. 8 vs. Buffalo Bills 4:25 p.m. ET Dec. 12 @ San Francisco 49ers 8:15 p.m. ET Dec. 22 @ New York Jets 1:00 p.m. ET TBD vs. Arizona Cardinals TBD TBD vs. Seattle Seahawks TBD If you purchase a product or register for an account through one of the links on our site, we may receive compensation. Learn more >
Elon Musk calls Trudeau 'insufferable tool' in new social media post
Firefighters and passengers hurt after train hits fire truck on crossingTHOUSAND OAKS, Calif. , Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the first quarter of 2025. The dividend will be paid on March 7, 2025 , to all stockholders of record as of the close of business on February 14, 2025 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-2025-first-quarter-dividend-302328180.html SOURCE Amgen